| Literature DB >> 28321237 |
Arintaya Phrommintikul1, Rungroj Krittayaphong2, Wanwarang Wongcharoen1, Smonporn Boonyaratavej3, Chaiyasith Wongvipaporn4, Woraporn Tiyanon5, Pakaphan Dinchuthai6, Rapeephon Kunjara-Na-Ayudhya7, Pyatat Tatsanavivat4, Piyamitr Sritara8.
Abstract
BACKGROUND: Coronary artery disease (CAD) is a leading cause of death in elderly because aging is the important non-modifiable risk factors of atherosclerosis and also a predictor of poor outcomes. Underuse of guideline directed therapy may contribute to suboptimal risk factor control and worse outcomes in the elderly. We aimed to explore the management of CAD, risk factors control as well as goal attainment in elderly compared to nonelderly CAD patients.Entities:
Keywords: Aging; Coronary artery disease; Goal attainment; Inequity; The elderly
Year: 2016 PMID: 28321237 PMCID: PMC5351825 DOI: 10.11909/j.issn.1671-5411.2016.12.002
Source DB: PubMed Journal: J Geriatr Cardiol ISSN: 1671-5411 Impact factor: 3.327
Clinical characteristic and risk factors of CAD patients.
| Nonelderly (< 65 years) ( | Elderly (≥ 65 years) ( | ||
| Age, yrs | 57.1 ± 5.1 | 73.2 ± 5.9 | < 0.001 |
| Female | 505 (25.9%) | 834 (38.4%) | < 0.001 |
| Chronic stable angina | 518 (26.6%) | 678 (31.2%) | 0.001 |
| Previous history of myocardial infarction | 1230 (63.1%) | 1229 (56.6%) | < 0.001 |
| Previous history of unstable angina | 252 (12.9%) | 299 (13.8%) | 0.436 |
| Polyvascular disease | 124 (6.4%) | 192 (8.8%) | 0.003 |
| Diabetes or received glucose lowering agents | 829 (42.6%) | 917 (42.2%) | 0.850 |
| Hypertension | 1317 (67.6%) | 1724 (79.4%) | < 0.001 |
| Dyslipidemia | 1474 (75.7%) | 1758 (80.9%) | < 0.001 |
| Family history of premature atherothrombosis | 173 (8.9%) | 137 (6.3%) | 0.002 |
| Chronic kidney disease | 241 (12.4%) | 489 (22.5%) | < 0.001 |
| eGFR | 71.6 ± 24.2 | 56.5 ± 20.8 | < 0.001 |
| Atrial fibrillation or atrial flutter | 51 (2.9%) | 125 (6.3%) | < 0.001 |
| Waist circumference | 89.0 ± 11.1 | 86.8 ± 11.6 | < 0.001 |
| BMI | 25.8 ± 7.8 | 24.3 ± 8.6 | < 0.001 |
Data were presented as mean ± SD or n (%). BMI: body mass index; CAD: coronary artery disease; eGFR: Estimated glomerular filtration rate.
Management of CAD.
| Nonelderly (< 65 years) ( | Elderly (≥ 65 years) ( | ||
| Percutaneous coronary intervention | 1252 (64.3%) | 1292 (59.5%) | 0.002 |
| Coronary artery bypass grafting | 195 (10.0%) | 291 (13.4%) | 0.001 |
| Medical treatment only | 534 (27.4%) | 638 (29.4%) | 0.167 |
| Aspirin | 1813 (93.1%) | 1944 (89.5%) | < 0.001 |
| P2Y12 inhibitor | 903 (46.4%) | 938 (43.2%) | 0.041 |
| Dual antiplatelet (aspirin and P2Y12 inhibitors) | 831 (42.7%) | 804 (37.0%) | < 0.001 |
| Warfarin | 66 (3.4%) | 97 (4.5%) | 0.079 |
| Statins | 1833 (94.1%) | 2044 (94.1%) | 1.000 |
| Ezetimibe | 101 (5.2%) | 109 (5.0%) | 0.832 |
| Statins and ezetimibe | 98 (5.0%) | 103 (4.7%) | 0.717 |
| Angiotensin converting enzyme inhibitor | 821 (42.2%) | 772 (35.5%) | < 0.001 |
| ARB | 484 (24.9%) | 697 (32.1%) | < 0.001 |
| ACEI or ARB | 1278 (65.6%) | 1442 (66.4%) | 0.598 |
| Beta blocker | 1623 (83.3%) | 1731 (79.7%) | 0.003 |
| Nitrate | 726 (37.3%) | 921 (42.4%) | 0.001 |
| Calcium channel blocker | 458 (23.5%) | 768 (35.4%) | < 0.001 |
| Antidiabetic agents | 639 (32.8%) | 687 (31.6%) | 0.423 |
| Insulin | 126 (6.5%) | 126 (5.8%) | 0.397 |
| Sulfonylurea | 368 (18.9%) | 374 (17.2%) | 0.168 |
| Metformin | 474 (24.3%) | 430 (19.8%) | < 0.001 |
| Thiazolidinedione | 68 (3.5%) | 59 (2.7%) | 0.176 |
| DDP4-inhibitor | 50 (2.6%) | 62 (2.9%) | 0.632 |
| Others | 31 (1.6%) | 29 (1.3%) | 0.517 |
Data were presented as n (%). ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CAD: coronary artery disease; DPP4: dipeptidyl peptidase-4.
Goal attainment of risk factor control.
| Risk factors | Nonelderly (< 65 years) ( | Elderly (≥ 65 years) ( | OR (95% CI) | Adjusted OR* (95% CI) | ||
| SBP <140 and DBP < 90 mmHg | 1387/1948 (71.2%) | 1394/2172 (64.2%) | 0.73 (0.64–0.83) | < 0.001 | 0.69 (0.59–0.80) | < 0.001 |
| LDL-C < 70 mg/dL | 223/1095 (20.4%) | 297/1169 (25.4%) | 1.33 (1.09–1.62) | 0.004 | 1.27 (1.02–1.57) | 0.033 |
| Sugar control (HbA1C < 7% or FBS < 140 mg/dL) | 834/1195 (69.8%) | 1005/1329 (75.6%) | 1.34 (1.13–1.60) | 0.001 | 1.57 (1.29–1.90) | < 0.001 |
| No current smoking | 1780/1,948 (91.4%) | 2082/2172 (95.9%) | 2.18 (1.68–2.84) | < 0.001 | 1.77 (1.32–2.36) | < 0.001 |
| ≥ 3 of 4 risk factors | 630/1369 (45.1%) | 751/1505 (49.9%) | 1.22 (1.05–1.41) | 0.009 | 1.23 (1.05–1.44) | 0.012 |
| All 4 risk factors | 100/1388 (7.2%) | 128/1505 (8.5%) | 1.21 (0.92–1.59) | 0.175 | 1.14 (0.85–1.53) | 0.371 |
*adjusted OR was adjusted by potential confounders including, gender, type of coronary artery disease, concurrent risk factors, body mass index, waist circumference, estimated glomerular filtration rate, medications. Data were presented as n (%). DBP: diastolic blood pressure; FBS: fasting blood sugar; LDL-C: low density lipoprotein cholesterol; SBP: systolic blood pressure.